36
Participants
Start Date
June 17, 2022
Primary Completion Date
April 30, 2024
Study Completion Date
February 28, 2026
Randomized: 40 mg Paltusotine
Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
Randomized: 80 mg Paltusotine
Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
Crinetics Study Site, New York
Crinetics Study Site, Stony Brook
Crinetics Study Site Peru #1, Lima
Crinetics Study Site Peru #2, Lima
Crinetics Study Site, Miami
Crinetics Study Site, Lexington
Crinetics Study Site, Columbus
Crinetics Study Site, Cleveland
Crinetics Study Site, Iowa City
Crinetics Study Site, Rochester
Crinetics Study Site, New Orleans
Crinetics Study Site, Querétaro City
Crinetics Study Site, Querétaro City
Crinetics Study Site, Houston
Crinetics Study Site, Los Angeles
Crinetics Study Site, Los Angeles
Crinetics Study Site, Newport Beach
Crinetics Study Site, Stanford
Crinetics Study Site, Criciúma
Crinetics Study Site, Boston
Crinetics Study Site, CABA
Crinetics Study Site, CABA
Crinetics Study Site, CABA
Crinetics Study Site, CABA
Crinetics Study Site, CABA
Crinetics Study Site, Fortaleza
Crinetics Study Site, Rio de Janeiro
Crinetics Study Site, Rio de Janeiro
Crinetics Study Site, Rio de Janeiro
Crinetics Study Site, São Paulo
Crinetics Study Site, Toronto
Crinetics Study Site, Mexico City
Crinetics Study Site, Katowice
Crinetics Study Site, Warsaw
Crinetics Study Site, Wroclaw
Lead Sponsor
Crinetics Pharmaceuticals Inc.
INDUSTRY